Search Results
Case 2: 17p-Deleted CLL Progressing on Ibrutinib Therapy
CLL: Optimal approaches for patients with deletion 17p
Real-world analysis of the impact of del(17p) on ibrutinib efficacy in CLL
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Case 4: Resistance to Ibrutinib in CLL
Case 1: The Use of Ibrutinib in CLL
Karyotyping a CLL subset with ibrutinib susceptibility
CLL: Long-term updates on ibrutinib and idelalisib
Case 1: Targeted Therapy: Ibrutinib for Newly Diagnosed CLL
Case 1: The Use of Ibrutinib in CLL
Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib
Highlight of CLL-related 2016 FDA approvals: Venetoclax
